anti-doping analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
=== Vector design === DNA vaccines elicit the best immune response when high-expression vectors are used. These are plasmids that usually consist of a strong viral promoter to drive the in vivo transcription and translation of the gene (or complementary DNA) of interest. Intron A may sometimes be included to improve mRNA stability and hence increase protein expression. Plasmids also include a strong polyadenylation/transcriptional termination signal, such as bovine growth hormone or rabbit beta-globulin polyadenylation sequences. Polycistronic vectors (with multiple genes of interest) are sometimes constructed to express more than one immunogen, or to express an immunogen and an immunostimulatory protein. Because the plasmid – carrying relatively small genetic code up to about 200 Kbp – is the "vehicle" from which the immunogen is expressed, optimising vector design for maximal protein expression is essential. One way of enhancing protein expression is by optimising the codon usage of pathogenic mRNAs for eukaryotic cells. Pathogens often have different AT-contents than the target species, so altering the gene sequence of the immunogen to reflect the codons more commonly used in the target species may improve its expression. Another consideration is the choice of promoter. The SV40 promoter was conventionally used until research showed that vectors driven by the Rous Sarcoma Virus (RSV) promoter had much higher expression rates.
Clobazam is predominantly a positive allosteric modulator at the GABAA receptor to increase GABAergic transmission, particularly chloride conductance in neurons and with some speculated additional activity at sodium channels and voltage-sensitive calcium channels. Clobazam binds at a distinct binding site associated with a Cl− ionophore at the GABAA receptor, increasing the duration of time for which the Cl− ionophore is open. The post-synaptic inhibitory effect of GABA in the thalamus is prolonged as a result. The exact mechanism of action for clobazam, a 1,5-benzodiazepine, which has anxiolytic and anticonvulsant effects similar to those produced by other benzodiazepine derivatives. Clobazam is a potent benzodiazepine receptor partial agonist at the GABAA receptor and the effects are related to binding to one or more specific GABA receptor subunits, increasing GABA-mediated inhibition. Clobazam is thought to involve the potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABAA receptor. Like other 1,5-benzodiazepines (for example, arfendazam, lofendazam, triflubazam, and CP-1414S), clobazam and the active metabolite N-desmethylclobazam have less affinity for the α1 subunit (sedative effects) of the GABAA receptor compared to the 1,4-benzodiazepines. They have a higher affinity for the α2 subunit (anxiolytic effects) and γ2 subunit of the GABAA receptor, which is essential for the anxiolytic and anticonvulsant effects of clobazam.
Processing of mRNA differs greatly among eukaryotes, bacteria, and archaea. Non-eukaryotic mRNA is, in essence, mature upon transcription and requires no processing, except in rare cases. Eukaryotic pre-mRNA, however, requires several processing steps before its transport to the cytoplasm and its translation by the ribosome.
As a result of its very low Lewis basicity, it is often used as a low-temperature solvent/diluent for superacids like magic acid (FSO3H/SbF5), allowing for highly reactive species like tert-butyl cation to be observed spectroscopically at low temperature (though tertiary carbocations do react with SO2 above about −30 °C, and even less reactive solvents like SO2ClF must be used at these higher temperatures).
==== Hierarchical deterministic wallet ==== The hierarchical deterministic (HD) wallet was publicly described in BIP32. As a deterministic wallet, it derives keys from a single master root seed, but instead of having a single "chain" of key pairs, an HD wallet supports multiple independent key pair chains. This allows a single seed to be used to generate an entire tree of key pairs with a stratified structure.
Sources: en.wikipedia.org
== History == The American professional wrestling promotion WWE (formerly World Wrestling Federation, or WWF) has been broadcasting pay-per-view (PPV) events since the mid 1980s, when its classic "Big Four" events (Royal Rumble, WrestleMania, SummerSlam, and Survivor Series) were first established between 1985 and 1989—with the company's very first PPV being WrestleMania in 1985. The company's PPV lineup expanded to a monthly basis in 1995 following the introduction of the In Your House series of pay-per views (which were replaced by standalone ppvs in 1999) before expanding even further in the mid-2000s during the first WWE brand extension. In addition, WWE produced international PPVs not available in the United States between 1997 and 2003. In 2022, the company began recognizing Money in the Bank as one of their five biggest events of the year, thus making it a "Big Five" event along with the classic "Big Four"; King of the Ring was considered a "Big Five" event from 1993 until 2002, after which, it was discontinued as a PPV until 2024. Following WWE's original brand extension in 2002, the company promoted two touring rosters, Raw and SmackDown, representing its television programs, Raw and SmackDown, with the two United Kingdom PPVs held that year being the first ones to be brand exclusive. Following Judgment Day in 2003, brand-exclusive PPVs were expanded to all WWE PPVs, except the traditional "Big Four", which continued to showcase the entire roster, while the remaining PPVs alternated between Raw and SmackDown.
The use of high-resolution ion-mobility mass spectrometry (IMS-MS) on HPLC-purified alpha-synuclein in vitro has shown alpha-synuclein to be autoproteolytic (self-proteolytic), generating a variety of small molecular weight fragments upon incubation. The 14.46 kDa protein was found to generate numerous smaller fragments, including 12.16 kDa (amino acids 14–133) and 10.44 kDa (40–140) fragments formed through C- and N-terminal truncation and a 7.27 kDa C-terminal fragment (72–140). The 7.27 kDa fragment, which contains the majority of the NAC region, aggregated considerably faster than full-length alpha-synuclein. It is possible that these autoproteolytic products play a role as intermediates or cofactors in the aggregation of alpha-synuclein in vivo.
There is not enough evidence to support the routine use of tranexamic acid to prevent bleeding in people with blood cancers. However, several trials are currently assessing this use of tranexamic acid. For people with inherited bleeding disorders (e.g. von Willebrand's disease), tranexamic acid is often given. It has also been recommended for people with acquired bleeding disorders (e.g., directly acting oral anticoagulants (DOACs)) to treat serious bleeding. The use of tranexamic acid, applied directly to the area that is bleeding or taken by mouth, appears useful to treat nose bleeding compared to packing the nose with cotton pledgets alone. It decreases the risk of rebleeding within 10 days.
In 2004, Maheshwari joined the University of Alabama at Birmingham, Alabama as an assistant professor. He studied innate immunity and the pathogenesis of gut mucosal and systemic inflammation in newborn infants, with a particular focus on a disease called necrotizing enterocolitis (NEC). In this disease, the intestines of a premature or critically ill infant become inflamed and lose viability. His research was supported by the American Gastroenterological Association and the National Institutes of Health. In 2010, he moved to the University of Illinois College of Medicine at Chicago, Illinois as the Head of Neonatology. In 2014, he was recruited to the University of South Florida as the Pamela and Leslie Muma Professor, Head of Neonatology, and Assistant Dean for Medical Education. He administered the academic and the clinical programs at the neonatal intensive care unit at Tampa General Hospital. In his laboratory, he investigated the role of intestinal macrophages and platelets in intestinal inflammation. In 2018, he relocated to the Johns Hopkins University School of Medicine, Baltimore, Maryland as the Josephine S. Sutland Professor of Newborn Medicine, Head of Neonatology, and vice-chairman of the Department of Pediatrics.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.